While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its ...

A small player like Viking may also win by attracting a partner or even a company that will offer to acquire the biotech.

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

As the battle against obesity and diabetes heats up, two new superstars are entering the ring in Spain - Mounjaro (also known ...

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide ... year – once-weekly injections of tirzepatide at three dose levels – 5, 10, and 15 mg – achieved a 94% reduction ...

The US pharma has just reported top-line results from the first phase 3 trial of its dual GLP-1/GIP agonist tirzepatide ... patients taking a weekly injectable dose of tirzepatide lost up to ...

Understanding the right dose of Ozempic for you can feel a bit confusing, especially if you're just getting started. While ...

Yes, it’s technically possible to overdose on Ozempic—but it’s unlikely, says Alexandra Sowa, MD, an internal medicine doctor ...

Eli Lilly and Co.’s recent decision to drop development at phase II of PD-1 agonist peresolimab in rheumatoid arthritis (RA) because of an inadequate benefit-risk profile brought further attention to ...

"I'm using [Ozempic] off-label for a whole host of conditions — and have been for years," Dr. Caroline Messer, an ...

Weight loss drugs like Ozempic and Wegovy may provide strong relief from severe osteoarthritis knee pain, new research finds.